RESUMO
Thechirality-controlled two-mode Lipkin-Meshkov-Glick (LMG) modelsare mimicked in a potential hybrid quantum system, involving two ensembles of solid-state spins coupled to a pair of interconnected surface-acoustic-wave cavities. With the assistance of dichromatic classical optical drives featuring chiral designs, it can simulate two-mode LMG-type long-range spin-spin interactions with left-right asymmetry. For applications, this unconventional LMG model can not only engineer both ensembles of collective spins into two-mode spin-squeezed states but also simulate novel quantum critical phenomena and time crystal behaviors, among others. Since this acoustic-based system can generate ion-trap-like interactions without requiring any additional trapping techniques, our work is considered a fresh attempt at realizing chiral quantum manipulation of spin-spin interactions using acoustic hybrid systems.
RESUMO
A proposal for simulating the Dicke-Lattice model in a mechanics-controlled hybrid quantum system is studied here. An array of coupled mechanical resonators (MRs) can homogeneously interact with a group of trapped Bose-Einstein condensates (BECs) via the gradient magnetic field induced by the oscillating resonators. Assisted by the classical dichromatic radio-wave fields, each subsystem with the BEC-MR interaction can mimic the Dicke type spin-phonon interaction, and the whole system is therefore extended to a lattice of Dicke models with the additional adjacent phonon-phonon hopping couplings. In view of this lattice model with theZ2symmetry, its quantum phase transitions behavior can be controlled by this periodic phonon-phonon interactions in the momentum space. This investigation may be considered as a fresh attempt on manipulating the critical behaviors of the collective spins through the external mechanical method.
RESUMO
Aim: We performed a meta-analysis to explore the efficacy of immunotherapy for patients with squamous non-small-cell lung cancer (NSCLC). Materials & methods: Randomized clinical trials comparing immunotherapy with chemotherapy for advanced NSCLC patients were included. Results: A total of 11 trials (3112 patients) were included. PD-1/PD-L1 inhibitors demonstrated significant superiority to chemotherapy in overall survival (OS) (hazard ratio [HR]: 0.74; p < 0.001) and progression-free survival (PFS) (HR: 0.66; p < 0.001) for squamous NSCLC. The OS and PFS benefits of PD-1/PD-L1 inhibitors for squamous NSCLC were similar in subgroup analyses of line settings, PD-L1 expression and different study methodologies. No advantage in OS was found in advanced squamous NSCLC patients treated with atezolizumab (HR: 0.87; p = 0.087). Conclusion: PD-1/PD-L1 inhibitors significantly improved OS and PFS in advanced squamous NSCLC patients when compared with chemotherapy.